We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Method Determines Optimal Number of Pathologists Needed for Correct Disease Diagnosis

By LabMedica International staff writers
Posted on 07 Feb 2022
Print article

A new method, named the Observers Needed for Evaluation of Subjective Tests (ONEST), has been developed to determine the optimal number of pathologists needed for a correct diagnosis.

The method developed by researchers at the Texas A&M University School of Public Health (College Station, TX, USA) could improve accuracy of disease diagnosis as pathology tests are mostly subjective, and even trained experts can disagree on results. The researchers developed a statistical framework to assess the performance of a diagnostic test with multiple observers. The proposed method includes an exploratory analysis, a statistical test of whether the observers’ agreement percentage will plateau to a non-zero value, and a statistical model to estimate the agreement percentage and the number of observers for reaching the plateau.

The method was applied in a non-small cell lung cancer example and a triple negative breast cancer example using reads of the immunohistochemical tests with SP142 and SP263 assays for expression of Programmed death-ligand 1 (PD-L1) to determine the number of observers needed for evaluation of the subjective tests. The proposed method can indicate whether adding more observers to a test causes the proportion of agreement to plateau. Cases where the curve does not plateau could indicate an unreliable test. In cases where the curve does flatten, the method indicates at least how many observers are needed to reach a stable and reliable estimation of their agreement.

Better understanding of how many observers are needed for optimal accuracy on a diagnostic test will help improve correct diagnosis, the right level of care and disease treatment. The researchers believe this method could be utilized by test creators and regulatory agencies to evaluate newly proposed subjective laboratory tests at different numbers of pathologists, which can ensure that the test will perform reliably in real-world settings.

Related Links:
Texas A&M University School of Public Health 

Gold Supplier
Ethanol/Ammonia Control
Liquichek Ethanol/Ammonia Control
Electrolyte Analyzer
K-Lite 5 Series
Silver Supplier
Receptor Destroying Enzyme
RDE II (Receptor Destroying Enzyme)
Molecular Diagnostic System
FlashDetect Flash48

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.